Carlson Capital’s Lantern Pharma LTRN Stock Holding History

Carlson Capital’s Portfolio LTRN Stock Details LTRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-60,000	Closed	-$257K	–	138
2023 Q4	$257K	Sell	60,000 -35,000	-37%	-$123K	0.02%	118
2023 Q3	$324K	Hold	95,000	–	–	0.03%	127
2023 Q2	$536K	Sell	95,000 -29,900	-24%	-$154K	0.05%	107
2023 Q1	$603K	Sell	124,900 -13,100	-9%	-$68.8K	0.06%	104
2022 Q4	$834K	Sell	138,000 -30,000	-18%	-$150K	0.06%	107
2022 Q3	$803K	Sell	168,000 -2,000	-1%	-$10.8K	0.06%	108
2022 Q2	$971K	Buy	170,000 +2,700	+2%	+$16.1K	0.07%	113
2022 Q1	$1.2M	Buy	167,300 +42,300	+34%	+$282K	0.08%	138
2021 Q4	$998K	Buy	+125,000	New	+$1.14M	0.06%	130

Other funds holding LTRN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Carlson Capital's LTRN Position: Q1 2024 in Review

Carlson Capital sold out of Lantern Pharma (LTRN) in Q1 2024, closing a stake of 60,000 shares — an estimated $257K sold.

Carlson Capital first reported a position in LTRN in Q4 2021 and held it in 9 quarters. The position peaked at $1.2M in Q1 2022. 34 funds tracked by Wall St. Rank hold LTRN as of Q1 2024.

Carlson Capital reported no remaining Lantern Pharma position as of Q1 2024 after selling out during the quarter.
Carlson Capital sold 60,000 Lantern Pharma shares in Q1 2024, an estimated $257K.
Carlson Capital first reported a position in Lantern Pharma in Q4 2021 and held it in 9 quarters.
Carlson Capital's Lantern Pharma position peaked at $1.2M in Q1 2022.
34 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2024.

Based on Carlson Capital's 13F filing for Q1 2024, filed 14 May 2024.